Tune & Track
Affinity Tuned CAR T Cells for Solid Tumors
Unlocking the Full Potential of CAR T Cell Therapies
AffyImmune is harnessing the power of the body’s own immune system to seek and destroy cancer cells by overcoming the immunotherapy challenges for solid tumors. AffyImmune’s proprietary “Tune & Track” technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues.
Science
Our core focus is on fine-tuning the affinity of CAR T cells to selectively kill tumor cells while sparing healthy cells to prevent toxicity and ensuring more natural, robust, and long-lasting activity of the CAR T cells. We engineer our CAR T cells to be monitorable in real-time in patients during treatment.
FEATURED NEWS
FEATURED JOBS
AffyImmune Therapeutics Announces Hiring of Dr. Sonal Gupta as Senior Vice President and Head of Clinical Development
NATICK, Mass. (APRIL 25, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today the addition of Sonal Gupta, MD, PhD to its senior leadership team as Senior Vice President [...]
Associate Director/Director of Clinical Biomarkers and CDx
AffyImmune Therapeutics (“Affy”), a clinical stage biotechnology company focused on creating technologies that expand the utility and improve the safety of cell-based immunotherapy for cancer, is seeking an Associate Director, Clinical Biomarkers and CDx (Director, depending on experience) to develop and commercialize companion diagnostic [...]